Literature DB >> 18409076

Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.

Kazuma Ohyashiki1, Toru Kiguchi2, Yoshikazu Ito2, Hiroaki Fujimoto2, Akihiko Gotoh2, Tetsuzo Tauchi2, Keisuke Miyazawa2, Yukihiko Kimura2, Junko H Ohyashiki3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18409076     DOI： 10.1007/s12185-008-0080-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Authors:  Alessandra Carobbio; Guido Finazzi; Vittoria Guerini; Orietta Spinelli; Federica Delaini; Roberto Marchioli; Giovanna Borrelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.

Authors:  K Ohyashiki; Y Aota; D Akahane; A Gotoh; J H Ohyashiki
Journal:  Leukemia       Date:  2007-02-22       Impact factor: 11.528

3.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Authors:  Guido Finazzi; Alessandro Rambaldi; Vittoria Guerini; Alessandra Carobbo; Tiziano Barbui
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

4.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

5.  Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.

Authors:  K Ohyashiki; Y Ito; K Hori; K Sato; T Makino; J H Ohyashiki
Journal:  Leukemia       Date:  2007-03-29       Impact factor: 11.528

6.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

7.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

Review 8.  WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.

Authors:  Jan Jacques Michiels; Hendrik De Raeve; Konnie Hebeda; King H Lam; Zwi Berneman; Wilfried Schroyens; Jiri Schwarz
Journal:  Leuk Res       Date:  2007-03-23       Impact factor: 3.156

9.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245
  9 in total
  4 in total

1.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

Review 2.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

3.  Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.

Authors:  Roberto Latagliata; Angela Rago; Antonio Spadea; Cristina Santoro; Ida Carmosino; Massimo Breccia; Laura Napoleone; Angelo Fama; Francesca Biondo; Paola Volpicelli; Federico Vozella; Caterina Stefanizzi; Maria Concetta Petti; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

4.  Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.

Authors:  Young-Uk Cho; Hyun-Sook Chi; Eun-Hye Lee; Seongsoo Jang; Chan-Jeoung Park; Eul-Ju Seo
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.